Q-omics provides the consensus-scored AGBL4 profile across patient tissues and cancer cell-line models. AGBL4 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, AGBL4 is differentially expressed in 11, with the highest sampling consensus in KIRC. Additionally, AGBL4 RNA expression shows 17,096 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight KIRC, and THYM as cancer lineages where AGBL4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for AGBL4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes AGBL4 survival associations across molecular data types. AGBL4 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible AGBL4 RNA expression–survival associations across cancer types. High AGBL4 expression shows unfavorable associations in UCEC, but favorable associations in KIRC, UVM, MESO, KIRP and BRCA. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for AGBL4 RNA expression.
This table summarizes AGBL4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for AGBL4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. AGBL4 shows lower tumor expression in KIRC, KICH, KIRP and THCA and higher tumor expression in COAD and BRCA. The KIRC box plot shows higher AGBL4 RNA expression in normal versus tumor tissue (log2 FC = −0.842, t-test p < 0.001).
This table shows molecular features associated with AGBL4 in patient tissues and cancer cell lines. In patient samples, AGBL4 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, AGBL4 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and BREAST.
